PharmaTimes October 15, 2024
John Pinching

Partnership to harness AI for DUB-focused preclinical programmes

Dundee-based Ubiquigent Limited and San Francisco’s Alleo Labs Corp have entered a strategic partnership to advance deubiquitinase (DUB)-focused drug discovery using AI.

The collaboration aims to combine Alleo’s AI-based platform with Ubiquigent’s expertise to speed up preclinical programmes targeting neurological diseases.

Under this partnership, Ubiquigent will gain exclusive access to Alleo’s AI software, RubDUB, to find novel DUB-modulating compounds.

These compounds are crucial for developing DUB inhibitors, DUB-targeting PROTACs, and DUB-Targeting Chimeras (DUBTACs). Meanwhile, Alleo will leverage Ubiquigent’s platforms to boost its in-house precision neuroscience programmes.

Jason Mundin, CEO of Ubiquigent, highlighted the potential of this collaboration: “The potential for the development of novel DUB-targeting therapeutics has never been greater, and this...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: AI (Artificial Intelligence), Biotechnology, Partnerships, Pharma, Pharma / Biotech, Technology, Trends
Related Articles:
More than half of US adults could benefit from GLP-1 medications, researchers find
RNA editing is the next frontier in gene therapy—here's what you need to know
Rand roadblock: Biotech bill’s uncertain future
How Digital Chemistry Will Improve Cross-Functional Collaboration In The Biopharma Industry
GLP-1 drug coverage for obesity making inroads with large employers: Mercer

Share This Article